New Director of Pharmacy Joins Minnesota Oncology

{image_1} Minnesota Oncology is pleased to introduce a new Director of Pharmacy Services, Paul Forsberg, PharmD, BCOP, MHA. Forsberg joined the practice in early October following the retirement of Jan Merriman, RPh, BCOP, after her nearly 20 years of pharmacy leadership at Minnesota Oncology.

Dr. Forsberg earned his PharmD degree from the University of Montana and received his Board Certification in Oncology Pharmacy (BCOP) in 2011. Earlier this year, Paul completed his Masters in Health Administration (MHA) degree from the University of Minnesota. For the past 4 years, Forsberg served as the Clinical Pharmacy Manager at St. John's Hospital in Maplewood, MN. 

“Paul has great experience in Twin Cities in providing oncology pharmacy leadership services,” said Dean Gesme, MD, president of Minnesota Oncology. “Previously he has worked  in a major health system as part of a clinical team to develop chemotherapy treatment plans, as well as medication related policies and procedures. We are fortunate to have his leadership in the ever-evolving oncology and hematology pharmacy services.”

Forsberg is the Vice President of the Upper Midwest Oncology Education Network and a current member of the Hematology/Oncology Pharmacy Association. He will serve on various councils at Minnesota Oncology, including the Co-Chair of the Pharmacy and Therapeutics Committee and the Co-Chair of the Clinical Practice Committee.

Share

Categories

Tags

Recent Posts

#
August 12, 2026

Learn why vaccines are an important part of cancer care, which vaccines may be recommended during treatment, and how to talk with your oncology team about the right timing.

#
July 30, 2026

Learn why staying up to date on recommended vaccines is important during and after cancer treatment, and how your oncology team can help determine the right immunizations for you.

#
July 28, 2026

Learn what makes sarcoma different from other cancers, including common symptoms, how it's diagnosed, and the treatment options available for this rare cancer of the body's connective tissues.